Search clinical trials for: Empagliflozin Linagliptin

Total 1551 results

AstraZeneca

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

Healthy Volunteer

China
Yangjin
Peking University Third Hospital

Not yet recruiting

Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients

Prediabetic State | Impaired Glucose Tolerance | Impaired Fasting Glucose

China
Merck Sharp & Dohme LLC

Completed

Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

Glucose Intolerance
Boehringer Ingelheim
Eli Lilly and Company

Completed

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Taiwan, Philippines, Australia, Hong Kong, Korea, Republic of, Canada, Italy, Malaysia, United Kingdom, Mexico, Greece, Spain, Netherlands, Switzerland, Israel, Portugal, Germany, Finland, Norway, Romania, Sweden, Serbia and more
McGill University Health Centre/Research Institute...

Recruiting

Empagliflozin in Acute Heart Failure (DRIP-AHF-1)

Chronic Kidney Diseases | Acute Heart Failure

Canada
Mount Sinai Hospital, Canada
Boehringer Ingelheim

Recruiting

Empagliflozin and the Preservation of Beta-cell Function in Women With Recent Gestational Diabetes (EMPA post-GDM)

Gestational Diabetes

Canada
Butler Hospital
National Institute of Mental Health (NIMH)

Completed

Antidepressant Medication for Reducing HIV Risk Behavior in Depressed Intravenous Drug Users

Substance-Related Disorders | Depression | HIV Infections

United States
Tanta University

Not yet recruiting

Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis

Non Alcoholic Steatohepatitis

Egypt
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease (SLIDE)

NAFLD | Non-Alcoholic Fatty Liver Disease | Pediatric NAFLD

United States
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Bioequivalence | Fixed Dose Combination Tablets | Healthy Male and Female Subjects

United States
Rehab Werida
University of Alexandria

Recruiting

Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)

Type 2 Diabetes | Nonalcoholic Fatty Liver Disease

Egypt
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Nanjing First Hospital, Nanjing Medical University; Wuxi People's Hospital; Changzhou... and other collaborators

Recruiting

Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function in T2DM Patients With Mild Cognitive Impairment: a Multicenter, Randomized, Parallel Controlled Clinical Trial (LIGHT-MCI)

Type 2 Diabetes Mellitus | Mild Cognitive Impairment

China
Maastricht University Medical Center

Recruiting

Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction

Heart Failure With Preserved Ejection Fraction | Microvascular Dysfunction

Netherlands
Matthieu Pelletier-Galarneau, MD MSc

Not yet recruiting

Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging (SWEET-HEART)

Myocardial Suppression
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Kidney Disease, Chronic

United States, Spain, Korea, Republic of, Belgium, Australia, Hong Kong, India, Canada, China, Germany, Italy, Japan, Malaysia, Finland, Switzerland, Turkey, Hungary, Poland, Portugal, Philippines, Czechia, Greece, Bulgaria, Brazil, Arg... and more
Medical University of Graz
Medical University of Vienna; Johannes Kepler University of Linz; Paracelsus... and other collaborators

Completed

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction (EMMY)

Acute Myocardial Infarction

Austria
Research Institute for Complex Problems of Cardiovascular...

Completed

Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions (SAFARY)

Coronary Artery Disease | Diabetes Mellitus | Percutaneous Coronary Intervention
National University of Malaysia

Unknown

Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD

Diabetes Mellitus | Chronic Kidney Diseases | Diabetic Retinopathy

Malaysia
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes (DERIVE)

Type 2 Diabetes Mellitus

United States, Italy, Spain, Sweden, Canada, Bulgaria, Poland, Czechia
Baylor College of Medicine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes

Type 1 Diabetes

United States
University of Alabama at Birmingham

Not yet recruiting

Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors

Obesity | Weight Loss

United States
The University of Hong Kong

Recruiting

Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics With Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM) (CATCH-EM)

Type 2 Diabetes | Microvascular Coronary Artery Disease

Hong Kong
University Hospital Tuebingen

Withdrawn

Empagliflozin Effect on Glucose Toxicity

Type2 Diabetes Mellitus

Germany
Rabin Medical Center

Unknown

Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department

DM2
Emory University
Merck Sharp & Dohme LLC

Terminated

DPP-4 Inhibition and TZD for DM Prevention (DInT DM)

Prediabetic State

United States
Nanjing First Hospital, Nanjing Medical University

Unknown

Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus
Chungbuk National University Hospital

Completed

Head-to-head Comparison of Empagliflozin and Dapagliflozin

Type2 Diabetes

Korea, Republic of
AstraZeneca

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

Chronic Kidney Disease and Hypertension

Spain, United States, Argentina, Denmark, Italy, Sweden, United Kingdom, Belgium, France, Turkey, China, Germany, Saudi Arabia, Thailand, Vietnam, Australia, Serbia, Brazil, Canada, Japan, Malaysia, Philippines, Poland, Taiwan, Greece, Is... and more
Newsoara Biopharma Co., Ltd.

Recruiting

Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM

T2DM

China
University Health Network, Toronto

Recruiting

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients (INFINITI2019)

Type 2 Diabetes | Kidney Transplant Recipients | Post-transplant Diabetes Mellitus

Canada
National Taiwan University Hospital
Shin Kong Wu Ho-Su Memorial Hospital

Not yet recruiting

Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease (EMPA-RRED)

Heart Failure With Reduced Ejection Fraction | End Stage Renal Disease on Dialysis
Ain Shams University
Drug Research Centre, Cairo, Egypt

Completed

The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin

Diabetes Mellitus | Pharmacokinetics | Pharmacodynamics

Egypt
AstraZeneca

Recruiting

Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

Type 2 Diabetes Mellitus (T2DM)

China
Hannover Medical School

Terminated

Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

Diabetes Mellitus, Type II

Germany
Biogen

Terminated

Natalizumab Subcutaneous Immunogenicity and Safety Study (SIMPLIFY)

Relapsing Multiple Sclerosis

Belgium
Biogen

Terminated

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring (INFORM)

Crohn's Disease

United States, Puerto Rico
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Canada, El Salvador, Germany, Italy, Portugal, Russian Federation, Spain, Ukraine
The George Institute
Victor Chang Cardiac Research Institute; St Vincent's Centre for Applied Medical...

Recruiting

Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial

Heart Failure With Preserved Ejection Fraction

Australia
Qingdao Central Hospital

Recruiting

The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction

Myocardial Infarction | Glucose Intolerance | Diabete Type 2

China
Saint Luke's Health System

Completed

Dapagliflozin in PRESERVED Ejection Fraction Heart Failure (PRESERVED-HF)

Chronic Heart Failure With Preserved Systolic Function

United States
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease (SHIELD)

Non-Alcoholic Fatty Liver Disease
Boehringer Ingelheim

Completed

A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together (InPedILD®)

Healthy

Brazil
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Linagliptin in Post-renal Transplantation

Transplanted Kidney Complication
Steno Diabetes Center Copenhagen
Novo Nordisk A/S

Unknown

Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria (EmpaSema)

Type 2 Diabetes With Renal Manifestations

Denmark
Boehringer Ingelheim

Completed

Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets

Healthy

Germany
Emory University
Boston Medical Center; Rush University; University of Denver

Completed

Linagliptin Inpatient Trial

Type 2 Diabetes

United States
Medical University of Lodz

Recruiting

Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease

Chronic Kidney Disease stage3

Poland
The Hospital for Sick Children
Juvenile Diabetes Research Foundation; Canadian Institutes of Health Research...

Active, not recruiting

Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial (ATTEMPT)

Diabetes Mellitus, Type 1

Canada, United States
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.

Diabetes Mellitus, Type 2

Korea, Republic of

Search clinical trials for: Empagliflozin Linagliptin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations